Srinagar, May 31 -- In a groundbreaking medical advancement, scientists have developed an artificial intelligence (AI) test capable of identifying which men with high-risk prostate cancer will benefit most from the life-extending drug abiraterone-a treatment shown to reduce the risk of death by nearly half.

Although abiraterone has been hailed as a "gamechanger" in prostate cancer care, some countries have limited its use to patients with advanced, spread-stage disease. The newly developed AI tool-created by researchers from the US, UK, and Switzerland-may help expand access by precisely identifying patients likely to respond to the drug before their cancer spreads.

The AI algorithm analyzes routine pathology slides, extracting subtle f...